Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
Schittenhelm MM, Kollmannsberger C, Oechsle K, Harlow A, Morich J, Honecker F, Kurek R, Störkel S, Kanz L, Corless CL, Wong KK, Bokemeyer C, Heinrich MC. Schittenhelm MM, et al. Among authors: oechsle k. Mol Cancer Ther. 2009 Mar;8(3):481-9. doi: 10.1158/1535-7163.MCT-08-1068. Epub 2009 Mar 10. Mol Cancer Ther. 2009. PMID: 19276157
Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C. Kollmannsberger C, et al. Among authors: oechsle k. Cancer. 2002 May 1;94(9):2353-62. doi: 10.1002/cncr.10494. Cancer. 2002. PMID: 12015760 Free article.
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
Hartmann JT, Oechsle K, Quietzsch D, Wein A, Hofheinz RD, Honecker F, Nehls O, Köhne CH, Käfer G, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: oechsle k. Br J Cancer. 2003 Dec 1;89(11):2051-6. doi: 10.1038/sj.bjc.6601412. Br J Cancer. 2003. PMID: 14647137 Free PMC article. Clinical Trial.
The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD. Pfannenberg AC, et al. Among authors: oechsle k. World J Urol. 2004 Jun;22(2):132-9. doi: 10.1007/s00345-003-0392-6. Epub 2004 Jan 21. World J Urol. 2004. PMID: 14735310
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
Hartmann JT, Oechsle K, Jäger E, Reis HE, Haag C, Niederle N, Wilke HJ, Pflüger KH, Batran SA, Büchele T, Hofheinz RD, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: oechsle k. Anticancer Drugs. 2004 Jun;15(5):473-7. doi: 10.1097/01.cad.0000127144.73043.57. Anticancer Drugs. 2004. PMID: 15166621 Clinical Trial.
144 results